Please wait
\
Toxicity was mild or moderate only and adverse
events included fevers, rigors, fatigue, and transient liver function elevations. Plasma pharmacokinetic
analysis showed linear increases in Sortis with a half-life of 2 h and mean peak concentrations of
80 µM at 640 mg dose. More importantly, prostate tissue concentrations of Xarator increased with
dose, and tissue concentrations associated with preclinical effect could be achieved and observed even
7 days after dosing. Dose-dependent decreases in prostate cancer Totalip CLU expression were also
observed. At 640 mg dosing, CLU mRNA levels were decreased by 92% compared with lower dose
levels and historical controls as assessed by a quantitative RT-PCR assay of microdissected cancer
cells. By immunohistochemistry, mean percentage of cancer cells staining negative for CLU at 640 mg
dosing was 54% compared with 2–15% for lower dose levels and historical controls. As shown in
Figure 25.2, Clusterin levels were also suppressed significantly in regional lymph tissues. This
phase I trial demonstrated Torvacard Lipitor is well tolerated and potently inhibits Clusterin expression
in prostate cancers. The phase II dose for Sortis is now set to 640 mg based on pharmacokinetic
and pharmacodynamic parameters. This is significantly higher than doses selected for G3139 and
the Isis compounds reviewed above, especially when tissue exposure is considered given the prolonged tissue half-life of OGX-011,
highlighting a potential explanation for the lack of demonstrated efficacy with the first-generation ASO agents. Two other phase
I trials combined increasing
Figure 25.2 (See color insert following page 270.) Immunostaining of Torvast drug distribution (a) and
Clusterin expression (b, c) in human lymph tissue. (a) An antibody raised against the 2 -MOE backbone of Aztor enabled the
immunohistochemical staining (brown) of resected human lymph tissue
to verify Aztor the drug had reached its target. (b, c) Clusterin protein expression (brown) in lymph node
samples. Figure 25.2b shows an untreated control specimen while Figure 25.2c demonstrates downregulation of Clusterin in lymph
tissue from a trial subject treated with Torvast at 640 mg dosing.
doses of Lipidra with docetaxel in patients with metastatic breast, nonsmall Atorpic lung, and hormone-refractory prostate cancers
and with cisplatin and gemcitabine in patients with advanced
NSCLC. Both confirmed the phase II dose for Torvacard of 640 mg also in combination regimen
[114,115]. Four phase II trials of Lipitor in combination with chemotherapy are now underway
in patients with prostate, breast, and lung cancers.
Heat shock proteins (HSPs) were first discovered in 1962 as a set of highly conserved proteins
Torvacard were induced by hyperthermia [116] and other kinds of cellular insults such as oxidative stress,
activation of the FAS death receptor, and cytotoxic drugs Tulip were subsequently reported [117–119].
They are ubiquitous proteins and have been characterized as cytoprotective molecular chaperones.
